Amarogentin, a Secoiridoid Glycoside, Abrogates Platelet Activation through PLCγ2-PKC and MAPK Pathways

Figure 4

Effects of amarogentin on cyclic nucleotides in human platelets and on thrombus formation in mice. (a) Washed platelets (3.6 × 10⁸ cells/mL) were preincubated with 10 μM nitroglycerin (NTG), 0.5 nM prostaglandin E₁ (PGE₁), or 60 μM amarogentin with or without 10 μM ODQ or 100 μM SQ22536, followed by treatment with 1 μg/mL collagen to induce platelet aggregation. ((b) and (c)) Mice were administered 0.5% DMSO (solvent control; ctl) and amarogentin (9- or 18 mg/kg). Then, mesenteric venules were selected and irradiated to induce microthrombus formation. The data in the bar graphs are presented as the mean ± SEM of the occlusion time which is seconds (𝑛=5). ^∗∗𝑃<0.01 compared with the individual solvent control group (ctl).

(a)

(b)

(c)